MetLife Investment Advisors LLC Buys Shares of 17,581 Global Blood Therapeutics Inc (GBT)

MetLife Investment Advisors LLC bought a new position in Global Blood Therapeutics Inc (NASDAQ:GBT) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 17,581 shares of the company’s stock, valued at approximately $692,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GBT. Perceptive Advisors LLC boosted its holdings in shares of Global Blood Therapeutics by 14.7% during the 4th quarter. Perceptive Advisors LLC now owns 4,889,066 shares of the company’s stock worth $192,384,000 after buying an additional 625,000 shares during the period. RTW Investments LP boosted its holdings in shares of Global Blood Therapeutics by 2,186.9% during the 4th quarter. RTW Investments LP now owns 601,683 shares of the company’s stock worth $23,676,000 after buying an additional 575,373 shares during the period. Millennium Management LLC boosted its holdings in shares of Global Blood Therapeutics by 4,463.4% during the 4th quarter. Millennium Management LLC now owns 479,838 shares of the company’s stock worth $18,882,000 after buying an additional 469,323 shares during the period. Citadel Advisors LLC boosted its holdings in shares of Global Blood Therapeutics by 161.7% during the 4th quarter. Citadel Advisors LLC now owns 716,611 shares of the company’s stock worth $28,199,000 after buying an additional 442,828 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in shares of Global Blood Therapeutics by 43.8% during the 3rd quarter. Janus Henderson Group PLC now owns 1,415,558 shares of the company’s stock worth $43,953,000 after buying an additional 431,325 shares during the period. 85.40% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

In other news, insider Jung Choi sold 3,000 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $62.95, for a total value of $188,850.00. Following the completion of the transaction, the insider now owns 140,877 shares in the company, valued at approximately $8,868,207.15. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Peter Radovich sold 30,000 shares of the stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $60.00, for a total transaction of $1,800,000.00. Following the completion of the transaction, the insider now owns 33,581 shares of the company’s stock, valued at approximately $2,014,860. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,911 shares of company stock valued at $2,362,352. Corporate insiders own 5.30% of the company’s stock.

A number of analysts have weighed in on the stock. BidaskClub raised shares of Global Blood Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 17th. Morgan Stanley increased their price target on shares of Global Blood Therapeutics from $58.00 to $61.00 and gave the company an “overweight” rating in a report on Tuesday, March 6th. Zacks Investment Research downgraded shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, March 6th. William Blair reissued a “buy” rating on shares of Global Blood Therapeutics in a report on Wednesday, February 28th. Finally, HC Wainwright set a $73.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a report on Wednesday, February 28th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $70.69.

Shares of GBT stock opened at $45.60 on Monday. Global Blood Therapeutics Inc has a 52-week low of $24.02 and a 52-week high of $68.05. The firm has a market capitalization of $2,369.17, a PE ratio of -16.52 and a beta of 4.37.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.22). sell-side analysts forecast that Global Blood Therapeutics Inc will post -3.72 earnings per share for the current year.

WARNING: This piece was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://ledgergazette.com/2018/04/16/metlife-investment-advisors-llc-buys-shares-of-17581-global-blood-therapeutics-inc-gbt.html.

About Global Blood Therapeutics

Global Blood Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase 3 clinical trials in adult and adolescent patients with sickle cell disease (SCD), as well as in evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase 2a clinical trial of adolescent and pediatric patients with SCD.

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply